{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Immune escape",
      "Reinfection",
      "SARS-CoV-2",
      "VOC",
      "Vaccine"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34252616",
  "DateCompleted": {
    "Year": "2021",
    "Month": "09",
    "Day": "13"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "07",
        "Day": "10"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.meegid.2021.104998",
      "S1567-1348(21)00295-1"
    ],
    "Journal": {
      "ISSN": "1567-7257",
      "JournalIssue": {
        "Volume": "94",
        "PubDate": {
          "Year": "2021",
          "Month": "Oct"
        }
      },
      "Title": "Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases",
      "ISOAbbreviation": "Infect Genet Evol"
    },
    "ArticleTitle": "New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil.",
    "Pagination": {
      "StartPage": "104998",
      "MedlinePgn": "104998"
    },
    "Abstract": {
      "AbstractText": [
        "After a one-year rollout of the pandemic caused by SARS-CoV-2, the continuous dissemination of the virus has generated a number of variants with increased transmissibility and infectivity, called variants of concern (VOC), which now predominate worldwide. Concerns about the susceptibility of humans that have already been infected before or those already vaccinated to infection by VOC rise among scientists and clinicians. Herein, we assessed the prevalence of different VOC among recent infections at the Brazilian National Cancer Institute (Rio de Janeiro, Brazil). By using a Sanger-based sequencing approach targeting the viral S gene to identify VOC, we have analyzed 72 recent infections. The overall prevalence of VOC was 97%. Among the subjects analyzed, six had been vaccinated with the ChAdOx1-S/nCoV-19 (n\u00a0=\u00a04; one with two doses and three with one dose) or the CoronaVac (n\u00a0=\u00a02; both with 2 doses) vaccine, while five subjects represented reinfection cases, being two of them also part of the vaccinated group (each one with one vaccine type). All vaccinated and re-infected subjects carried VOC irrespective of the vaccine type taken, the number of doses taken, IgG titers or being previously infected during the first wave of the Brazilian pandemic. Importantly, all six vaccinees only had mild symptoms. We present here several examples of how natural infections or vaccination may not be fully capable of conferring sterilizing immunity against VOC."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: livia.goes@inca.gov.br."
          }
        ],
        "LastName": "Goes",
        "ForeName": "Livia R",
        "Initials": "LR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: juliana.siqueira@inca.gov.br."
          }
        ],
        "LastName": "Siqueira",
        "ForeName": "Juliana D",
        "Initials": "JD"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Hospital Infection Control Committee, Brazilian National Cancer Institute, Pra\u00e7a Cruz Vermelha, 23, Rio de Janeiro, RJ 20230-130, Brazil. Electronic address: Marianne.Monteiro@inca.gov.br."
          }
        ],
        "LastName": "Garrido",
        "ForeName": "Marianne M",
        "Initials": "MM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: brunnamisael@gmail.com."
          }
        ],
        "LastName": "Alves",
        "ForeName": "Brunna M",
        "Initials": "BM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Section of Anesthesiology, Brazilian National Cancer Institute, Pra\u00e7a Cruz Vermelha, 23, Rio de Janeiro, RJ 20230-130, Brazil. Electronic address: ana.pinho@inca.gov.br."
          }
        ],
        "LastName": "Pereira",
        "ForeName": "Ana Cristina P M",
        "Initials": "ACPM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: ccicala@niaid.nih.gov."
          }
        ],
        "LastName": "Cicala",
        "ForeName": "Claudia",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: jarthos@niaid.nih.gov."
          }
        ],
        "LastName": "Arthos",
        "ForeName": "James",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Program of Immunology and Tumor Biology, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: jpviola@inca.gov.br."
          }
        ],
        "LastName": "Viola",
        "ForeName": "Jo\u00e3o P B",
        "Initials": "JPB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Department of Genetics, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro, RJ 21941-590, Brazil. Electronic address: masoares@inca.gov.br."
          }
        ],
        "LastName": "Soares",
        "ForeName": "Marcelo A",
        "Initials": "MA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "CollectiveName": "INCA COVID-19 Task Force\u02c6"
      }
    ],
    "GrantList": [
      {
        "GrantID": "ZIA AI001273",
        "Acronym": "ImNIH",
        "Agency": "Intramural NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Intramural",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Infect Genet Evol",
    "NlmUniqueID": "101084138",
    "ISSNLinking": "1567-1348"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Brazil"
    },
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology",
        "immunology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Phylogeny"
    },
    {
      "QualifierName": [
        "classification",
        "genetics",
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccination"
    }
  ],
  "CoiStatement": "none."
}